CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

20-478 / S -007

ADMINISTRATIVE DOCUMENTS AND CORRESPONDENCE

Division of Anesthetic, Critical Care, and Addiction Drug Products

REGULATORY PROJECT MANAGER
LABELING REVIEW

Application Number: NDA 20-478/SLR-007

Name of Drug: Ultane® (sevoflurane)

Sponsor: Abbott Laboratories

Supplement Number under review:

Package Insert, label, and carton:
SLR-007 AF, October 28, 2002, received October 29, 2002.

RPM: Lisa E. Basham-Cruz
Date of Review: December 3, 2002

Background and Summary Description: SLR-007, dated August 18, 2000, proposed changes in the DESCRIPTION section to include a [redacted] This change, however, was never supported formally in a chemistry supplement. Therefore, SLR-007 was rendered approvable pending the approval of a chemistry supplement supporting the change in [redacted] The chemistry supplement (S-009), submitted March 28, 2001, was approved on September 28, 2001. Upon approval of S-009, the labeling changes proposed in SLR-007 were readdressed. A second approvable letter was issued August 9, 2002. The resubmission in response to the August 9, 2002, approvable letter is the subject of this review.

Material Reviewed:

Package Insert: SLR-007; AF submission, dated October 28, 2002, compared with SLR-010: approved August 10, 2001.
Label and Packaging: SLR-007 AF submission, dated October 28, 2002, compared with SLR-007, dated August 18, 2000, and approvable letter dated August 9, 2002.

Review

Please note that, where appropriate, the sponsor's revisions are indicated by strikeovers and underlined text.

PACKAGE INSERT

BOX WARNING: Not applicable

DESCRIPTION:

Sevoflurane is a clear, colorless, ~~stable~~ liquid containing no additives ~~or chemical stabilizers~~. Sevoflurane is nonpungent. It is miscible with ethanol, ether, chloroform, and ~~petroleum~~ benzene, and it is slightly soluble in water. Sevoflurane is stable when stored under normal room lighting conditions according to instructions.

~~Sevoflurane is chemically stable. No discernible degradation occurs in the presence of strong acids or heat.~~ The only known degradation reaction in the clinical setting is through direct contact with CO_2 absorbants (soda lime and Baralyme®) producing pentafluoroisopropenyl fluoromethyl ether....

CLINICAL PHARMACOLOGY: No changes noted.

PHARMACOKINETICS: No changes noted.

PHARMACODYNAMICS: No changes noted.

INDICATIONS AND USAGE: No changes noted.

CONTRAINDICATIONS: No changes noted.

WARNINGS: No changes noted.

PRECAUTIONS: No changes noted.

ADVERSE REACTIONS: No changes noted.

OVERDOSAGE: No changes noted.

DOSAGE AND ADMINISTRATION: No changes noted.

HOW SUPPLIED: No changes noted.

SAFETY AND HANDLING: No changes noted.

STORAGE: No changes noted.

LABEL AND PACKAGING

Abbott has committed to make the minor changes required in the Agency approvable letter, dated August 9, 2002, in their next printing. The references to [redacted] proposed in the form of draft labeling in the original SLR-007 submission, dated August

18, 2002, have been removed from the draft label and packaging resubmitted on October 28, 2002 (SLR-007; AF).

Conclusions:
The changes in the label are identical to those identified by the Agency as required for approval in the August 9, 2002, approvable letter. The labeling supplement may be approved.

_____
Lisa E. Basham/Regulatory Project Manager

_____
Parinda Jani/Supervisory Comment/Concurrence

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Lisa Basham-Cruz
12/9/02 12:49:53 PM
CSO

Parinda Jani
12/10/02 11:19:01 AM
CSO

NDA 20478

Abbott Laboratories
200 Abbott Park Rd. Bldg. AP30
Abbott Park, Illinois 60064-6157

Attention: Lisa K. Zboril, Associate Director
Hospital Products Division, Regulatory Affairs

Dear Ms. Zboril:

We have received your supplemental drug application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for the following:

Name of Drug Product: Ultane (sevoflurane)

NDA Number: 20-478

Supplement Number: S-007

Date of Supplement: August 18, 2000

Date of Receipt: August 21, 2000

Reference is made to our September 18, 2000, telephone conversation. As discussed, this supplemental application, submitted as a "Supplement - Changes Being Effected in 30 days" supplement, proposes changes in the package insert regarding the presence of water. Changes of this kind cannot be put into effect prior to approval of a supplement. An approved supplement is required for these proposed changes.

Unless we notify you within 60 days of our receipt date that the application is not sufficiently complete to permit a substantive review, this application will be filed under section 505(b) of the Act on October 20, 2000, in accordance with 21 CFR 314.101(a).

Please cite the application number listed above at the top of the first page of any communications concerning this application. All communications concerning this supplemental application should be addressed as follows:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Anesthetic, Critical Care, and Addiction Drug Products, HFD-170
Attention: Division Document Room
5600 Fishers Lane

Rockville, Maryland 20857

If you have any questions regarding this correspondence, please call me at 301-827-7420.

Sincerely,

Lisa E. Basham
Regulatory Project Manager
Division of Anesthetic, Critical Care, and Addiction
Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

cc:
Archival NDA 20478
HFD-170/Div. Files
HFD-170/L.Basham, C.Schumaker
HFD-358/D.MorleyDISTRICT OFFICE

Drafted by: LEB/September 18, 2000
Initialed by: CS9/19/00, 9/20/00
final: LEB9/20/00
filename: S007ACK.DOC

PRIOR APPROVAL SUPPLEMENT ACKNOWLEDGEMENT (AC)